Abstract
BackgroundIn ACT-RAY, MTX-IR patients (pts) with moderate to severe RA were randomized to either an add-on (tocilizumab [TCZ]+MTX) or a switch (TCZ+placebo [PBO]) strategy. Data at 24 and 52 weeks...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have